---
schema_version: "secwatch.filing_event.v1"
accession: "0001551306-22-000038"
form_type: "8-K"
ticker: "PGNY"
cik: "0001551306"
company_name: "Progyny, Inc."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:43:47.376386+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Progyny raises FY2022 guidance after Menopur supply resumes; revenue now $781.5-$786.5M

## Summary
- Revenue guidance raised to $781.5-786.5M (56-57% YoY growth) for full year 2022.
- Net income guided to $28.5-29.5M ($0.28-0.29 diluted EPS); adjusted EBITDA $124-125.5M.
- Q4 2022 revenue projected at $208.9-213.9M (64-68% growth); net income $1.5-2.5M.
- Guidance increase due to resumed shipments of Menopur, a key fertility medication, after industry-wide shortage.
- Company now serves >370 clients representing 5.4 million members as it enters 2023.

## SEC filing metadata
- accession: 0001551306-22-000038
- form_type: 8-K
- ticker: PGNY
- cik: 0001551306
- company_name: Progyny, Inc.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551306/000155130622000038/0001551306-22-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551306/000155130622000038/pgny-20221128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551306-22-000038
- JSON: https://secwatch.observer/filing/0001551306-22-000038.json
- Plain text: https://secwatch.observer/filing/0001551306-22-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.